All In Biotech

Drug Trial Radar · NCT07208591

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Phase Ⅲ Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 406 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

406

Planned (sponsor's estimate)

Start

Oct 31, 2025

Primary completion

Jul 2026

Study completion Oct 2026

Sponsor

Sponsor type
Industry
First posted
Oct 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome

Conditions

  • Acute Respiratory Distress Syndrome (ARDS)

Interventions

  • STSA-1002 injectionDrug

    basal treatment + STASA-1002 intravenous infusion

  • STSA-1002 Injection PlaceboDrug

    basal treatment + STSA-1002 Injection Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day all-cause mortality rateTime frame: Day28 after first dose

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • The Third Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • The Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Wuhan Central Hospital

    Wuhan, Hubei, China · Recruiting

  • Xiangtan Central Hospital

    Xiangtan, Hunan, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Weifang People's Hospital

    Weifang, Shandong, China · Recruiting

  • Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • Dazhou Central Hospital

    Dazhou, Sichuan, China · Recruiting

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.